Viatris Reports Q2 Revenue Drop, Sees Growth in Greater China Amid Global Decline
Company

Viatris Reports Q2 Revenue Drop, Sees Growth in Greater China Amid Global Decline

Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter
CompanyDeals

Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter

Teleflex's Rüsch EZ-Blocker Gets NMPA Approval for China Market
CompanyDrug

Teleflex’s Rüsch EZ-Blocker Gets NMPA Approval for China Market

Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million
CompanyDeals

Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million

Haisco's HSK47388 Receives NMPA Clinical Trial Approval for Autoimmune Diseases
CompanyDrug

Haisco’s HSK47388 Receives NMPA Clinical Trial Approval for Autoimmune Diseases

HutchMed Reports 9% Revenue Dip in H1 2025; FRUZAQLA Sales Grow Despite Overall Decline
Company

HutchMed Reports 9% Revenue Dip in H1 2025; FRUZAQLA Sales Grow Despite Overall Decline

Westgene Partners with BGI Huo-Yan for mRNA Drug Development and Industrialization
CompanyDeals

Westgene Partners with BGI Huo-Yan for mRNA Drug Development and Industrialization

Henlius' HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment
CompanyDrug

Henlius’ HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment

Cryofocus Medtech's Cryoadhesion System Gains NMPA Approval for Commercialization
CompanyMedical Device

Cryofocus Medtech’s Cryoadhesion System Gains NMPA Approval for Commercialization

Zai Lab Announces Q2 2025 Results With 10% Revenue Growth Driven by Key Products
Company

Zai Lab Announces Q2 2025 Results With 10% Revenue Growth Driven by Key Products

Sino Biopharmaceutical's LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors
CompanyDrug

Sino Biopharmaceutical’s LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors

Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data
CompanyDrug

Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data